Evondos strengthens its commercial, technology and financial leadership as the company builds on its growth across eight markets and prepares for its next phase of international expansion and scale.
Over the past years, Evondos has grown significantly, building a leading position across eight markets, a strong product offering and high service levels. As the company enters its next phase, the focus is increasingly on scaling the business, strengthening collaboration across markets and building repeatable ways of working that can support continued international growth.
In addition, the company prepares for the introduction of several new products in 2027, including Mira, its next-generation automated medication dispenser, and EvondosCare, the new cloud-based connectivity platform.
To support these developments, Evondos is strengthening its Executive Team with the appointments of Lucille Wagschal as Chief Commercial Officer, Marshall Van Beurden as Chief Technology Officer and Leo Toole as Chief Financial Officer.
Strengthening international commercial leadership
As of November 2, Lucille Wagschal has joined Evondos as Chief Commercial Officer and a member of the Executive Team. She brings 26 years of experience across commercial and finance roles, including extensive experience in healthcare. Most recently, she held senior leadership roles at Baxter, accelerating growth within Front Line Care across primary and long-term care channels through strengthened commercial focus and execution, while also driving go-to-market transformation and strategic growth initiatives across Western Europe within Healthcare Systems & Technologies.
In her new role, Lucille will lead Evondos’ marketing & sales organisation across its markets. With her broad international experience, she will focus on bringing markets closer together, strengthening commercial execution and developing scalable ways of working as Evondos continues to grow in existing and new markets.
Markus Mäkelä, who has led Evondos’ commercial organisation as Chief Commercial Officer, takes on the role of VP Sales Operations Nordics. In this role, Markus will focus on the Nordic markets, tenders and pricing, and partnerships, drawing on his extensive experience and deep knowledge of Evondos’ customers and markets.
Advancing Evondos’ technology and platform ambitions
As of November 2, Marshall Van Beurden joined Evondos as Chief Technology Officer and a member of the Executive Team. Marshall brings more than 25 years of experience in technology, including building platforms for enterprise customers and supporting international expansion in regulated environments. His experience also includes the launch of new products at AWS, Miro and healthcare company myTomorrows.
Marshall’s appointment comes as Evondos continues its evolution towards becoming a broader platform company. While automated medication dispensing devices remain at the core of the business, the company’s technology offering is increasingly expanding into software, cloud services and integrations.
Per the same date Ville Saarainen will step down from the CTO role he has held for six years and will transition out quarter one 2027. During Ville’s tenure, Evondos has grown to more than €70 million in revenue, serving more than 50.000 users in 8 countries. He has played a crucial role in building Evondos’ technology organisation and led the development of Mira and EvondosCare, which have now achieved their CE mark and are launching in the Nordic markets.
Strengthening financial leadership for continued growth
Leo Toole has been appointed Chief Financial Officer and joined the Executive Team in October.
He brings extensive CFO and board-level experience from both established corporate organisations and start-up and scale-up environments. He holds an MBA from INSEAD and has a strong track record in fundraising, scaling businesses for growth, change management and supporting breakthrough life science technologies.
As CFO, Leo will help strengthen the financial capabilities and structures needed to support Evondos as the company continues to scale internationally.
“Evondos has built a strong foundation in 8 markets, and we are now preparing for our next phase of international growth. Lucille, Marshall and Leo bring very valuable experience across commercial, technology and finance that will help us scale and bring our solutions to more people and care organisations,” says Frans Cromme, CEO of Evondos.
“I’m also very pleased that Markus will continue to strengthen our Nordic business, and I want to sincerely thank Ville for the important role he has played in building Evondos into the company we are today.
Media Contact
Rory Heaslip
Director of Marketing, Communications & PR
rory.heaslip@evondos.com
Mobile: +44 077 37790632
About Evondos
Evondos is a European healthtech company and one of Europe's largest providers of automated medication dispensing services. Operating across eight European markets, the company supports care providers, health regions and municipalities in addressing increasing care demands while enabling people to live independently at home for longer.
Medication management remains at the heart of Evondos' offering. Through its market-leading automated medication dispensing service, the company helps ensure safe and timely medication intake, improve adherence and free up valuable time for care professionals.
Building on its strong position in medication management, Evondos is expanding its portfolio of digital care solutions through ongoing product development, software innovation and strategic growth initiatives. By combining established MedTech solutions with broader HealthTech capabilities, the company helps customers improve efficiency, increase capacity and deliver more person-centred care.
Today, Evondos supports more than 50,000 people and over 700 municipalities, regions and care organisations across Europe. As a healthcare company powered by technology and delivered by people who care, Evondos is committed to giving time back to care professionals, care organisations and the people who rely on care every day.
